Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2022 | Targeting α-synuclein & neuroinflammation in Parkinson’s disease

Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, Rome, Italy, gives an update on novel neuroprotective strategies and targets under development for the treatment of Parkinson’s disease (PD). To date, there is no existing neuroprotective or neurorestorative therapy for treating PD. However, targeting α-synuclein is a disease-modifying therapeutic strategy currently in development. Several immunotherapeutic approaches are being evaluated in clinical trials, including passive immunization based on antibodies against the protein. Another promising approach is targeting neuroinflammation to halt or slow down disease progression. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.